00:47 , Jun 29, 2019 |  BioCentury  |  Finance

All eyes on new modality launches, cancer and rare disease data in 3Q19

While the typical summer lull means fewer catalysts in the third quarter, investors will be keeping a close eye on launches of new modality drugs. Of special interest to multiple buysiders is the launch of...
20:03 , Jul 6, 2018 |  BioCentury  |  Emerging Company Profile

Tethering bleeding risk

With a mechanism that blocks thrombosis-contributing cells but not coagulation, Tetherex Pharmaceuticals Inc.’s pan-selectin inhibitor SelK2 could treat venous thromboembolism with little to no risk of bleeding. Chairman and CEO Scott Rollins said while antithrombotic...
19:04 , Mar 23, 2018 |  BC Week In Review  |  Financial News

GlycoMimetics reaps $119M in bumped-up follow-on

GlycoMimetics Inc. (NASDAQ:GLYC) raised $119 million on March 20 through the sale of 7 million shares at $17 in an upsized follow-on underwritten by Jefferies, Cowen, Stifel, SunTrust Robinson Humphrey and Roth Capital Partners. The...
17:08 , Mar 21, 2018 |  BC Extra  |  Financial News

GlycoMimetics reaps $119M in bumped-up follow-on

GlycoMimetics Inc. (NASDAQ:GLYC) raised $119 million through the sale of 7 million shares at $17 in an upsized follow-on underwritten by Jefferies, Cowen, Stifel, SunTrust Robinson Humphrey and Roth Capital Partners. The price is a...
00:00 , Mar 7, 2018 |  BC Extra  |  Clinical News

GlycoMimetics falls on Phase III AML trial design

GlycoMimetics Inc. (NASDAQ:GLYC) lost $4.07 (18%) to $18.75 on Tuesday after the company unveiled late Monday the design of its Phase III trial for acute myelogenous leukemia candidate GMI-1271. The primary endpoint of the trial,...
02:15 , Dec 16, 2017 |  BioCentury  |  Product Development

Assessing the BCMA scene

Differences in patient populations and a dearth of clinical outcome data mean it’s too soon to declare bluebird bio Inc.’s anti-BCMA chimeric antigen receptor therapy the leader of the pack of CARs that presented clinical...
17:02 , Dec 15, 2017 |  BC Week In Review  |  Clinical News

GlycoMimetics reports updated Phase I/II AML data for GMI-1271

GlycoMimetics (NASDAQ:GLYC) reported updated data at the American Society of Hematology meeting from a Phase I/II trial of GMI-1271 to treat acute myelogenous leukemia (AML). The company plans to start a Phase III trial in...
21:58 , Dec 12, 2017 |  BC Extra  |  Clinical News

GlycoMimetics gains on updated AML data at ASH

GlycoMimetics jumped $2.13 (15%) to $16.45 on Tuesday after reporting updated data at the American Society of Hematology meeting from a Phase I/II trial of GMI-1271 to treat acute myelogenous leukemia. The company plans to...
18:34 , Jun 9, 2017 |  BioCentury  |  Regulation

New SOC in sickle cell?

If FDA follows ODAC’s recommendation to approve Endari L-glutamine from Emmaus Life Sciences Inc. , the candidate is likely to become the backbone of sickle cell therapy. On May 24, FDA’s Oncologic Drugs Advisory Committee...
12:30 , May 26, 2017 |  BC Week In Review  |  Clinical News

GlycoMimetics reports Phase I/II OS data for SELE-targeting AML candidate

In an abstract released ahead of the American Society of Clinical Oncology meeting in Chicago next month, GlycoMimetics Inc. (NASDAQ:GLYC) reported Phase I/II data showing that twice-daily GMI-1271 plus mitoxantrone, etoposide and cytarabine (MEC) led...